MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease

  • Authors:
    • Chen-Geng Liu
    • Jin-Ling Wang
    • Lei Li
    • Pei-Chang Wang
  • View Affiliations

  • Published online on: May 13, 2014     https://doi.org/10.3892/ijmm.2014.1780
  • Pages: 160-166
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Amyloid precursor protein (APP) and β-site APP cleaving enzyme (BACE-1) play important roles in the pathogenesis of Alzheimer's disease (AD). In this study, using bioinformatics analysis, we demonstrate that miR-384 is a microRNA (miRNA or miR) predicted to potentially target the 3' untranslated regions (3'-UTRs) of both APP and BACE-1. SH-SY5Y cells were transfected with miR-384 mimic oligonucleotide, miR-384 inhibitor oligonucleotide, or a non-specific control siRNA. We found that the overexpression of miR-384 suppressed the mRNA and protein expression of both APP and BACE-1. The miR-384 inhibitor oligonucleotide induced the upregulation of APP and BACE-1. The activity of BACE-1 was altered following the change in its protein expression. The binding sites of miR-384 on the 3'-UTRs of APP and BACE-1 were identified by luciferase assay. Furthermore, cells were treasted with amyloid-β (Aβ)42. Aβ42 downregulated miR-384 expression, leading to the continuous reduction in miR-384 expression. In addition, using a mouse model of AD, as well as patients with mild cognitive impairment (MCI) and dementia of Alzheimer's type (DAT), we examined the levels of miR-384 in cerebral spinal fluid (CSF) and serum. Patients with MCI and DAT had lower blood miR-384 levels compared with the controls. In addition, patients with DAT had lower blood miR-384 levels in blood compared with the MCI group. We also found decreased miR-384 expression in the several cerebral spinal fluid (CSF) of the patients with DAT. Negative correlations were observed between miR-384 and Aβ42 in the serum and CSF from patients with AD. In conclusion, these findings demonstrate that miR-384 may plays a role in the development of AD and may be a potential non-invasive biomarker for the diagnosis of AD.

References

1 

Weiner MW: Dementia in 2012: further insights into Alzheimer disease pathogenesis. Nat Rev Neurol. 2:65–66. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Singer O, Marr RA, Rockenstein E, et al: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 8:1343–1349. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Tan L, Yu JT, Hu N and Tan L: Non-coding RNAs in Alzheimer’s disease. Mol Neurobiol. 47:382–393. 2013.

4 

Junn E and Mouradian MM: MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther. 133:142–150. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Schonrock N, Matamales M, Ittner LM and Götz J: MicroRNA networks surrounding APP and amyloid-β metabolism - implications for Alzheimer’s disease. Exp Neurol. 235:447–454. 2012.PubMed/NCBI

6 

Boissonneault V, Plante I, Rivest S and Provost P: MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem. 284:1971–1981. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Faghihi MA, Modarresi F, Khalil AM, et al: Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 14:723–730. 2008.

8 

Blennow K, Hampel H, Weiner M and Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 6:131–144. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Zetterberg H, Andreasson U, Hansson O, et al: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 65:1102–1107. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Schonrock N, Ke YD, Humphreys D, et al: Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. PLoS One. 5:e110702010.PubMed/NCBI

11 

Patel N, Hoang D, Miller N, et al: MicroRNAs can regulate human APP levels. Mol Neurodegener. 3:102008. View Article : Google Scholar : PubMed/NCBI

12 

Wei PC, Tsai CH, Chiu PS and Lai SC: Matrix metalloproteinase-12 leads to elastin degradation in BALB/c mice with eosinophilic meningitis caused by Angiostrongylus cantonensis. Int J Parasitol. 41:1175–1183. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Schonrock N, Humphreys DT, Preiss T and Götz J: Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. J Mol Neurosci. 46:324–335. 2012.PubMed/NCBI

14 

Lindner DJ, Wu Y, Haney R, et al: Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol. 32:123–132. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Liu CG, Xu KQ, Xu X, et al: 17Beta-oestradiol regulates the expression of Na+/K+-ATPase beta1-subunit, sarcoplasmic reticulum Ca2+-ATPase and carbonic anhydrase iv in H9C2 cells. Clin Exp Pharmacol Physiol. 34:998–1004. 2007.PubMed/NCBI

16 

Giedraitis V, Sundelöf J, Irizarry MC, et al: The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer’s disease. Neurosci Lett. 427:127–131. 2007.PubMed/NCBI

17 

Dassow H and Aigner A: MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr Pharm Des. 19:1242–1252. 2013.PubMed/NCBI

18 

Zhang Y, Liu D, Chen X, et al: Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 39:133–144. 2010. View Article : Google Scholar : PubMed/NCBI

19 

van Leuven F: Single and multiple transgenic mice as models for Alzheimer’s disease. Prog Neurobiol. 61:305–312. 2000.

20 

Ma R, Jiang T and Kang X: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 31:382012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2014
Volume 34 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, C., Wang, J., Li, L., & Wang, P. (2014). MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease. International Journal of Molecular Medicine, 34, 160-166. https://doi.org/10.3892/ijmm.2014.1780
MLA
Liu, C., Wang, J., Li, L., Wang, P."MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease". International Journal of Molecular Medicine 34.1 (2014): 160-166.
Chicago
Liu, C., Wang, J., Li, L., Wang, P."MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease". International Journal of Molecular Medicine 34, no. 1 (2014): 160-166. https://doi.org/10.3892/ijmm.2014.1780